CASI Pharmaceuticals administers first FOLOTYN dose in China for PTCL treatment

Pallavi Madhiraju- February 18, 2024 0

In a significant stride toward addressing the critical medical needs of peripheral T-cell lymphoma (PTCL) patients in China, CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a trailblazer ... Read More

Prescient Therapeutics gets FDA orphan drug status for PTX-100 in PTCL

pallavi123- July 15, 2022 0

Prescient Therapeutics has secured the orphan drug designation for its PTX-100 compound from the US Food and Drug Administration (FDA) for the treatment of peripheral ... Read More

Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn

pallavi123- August 27, 2021 0

US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More

Takeda gets extended EC approval for ADCETRIS in sALCL

pharmanewsdaily- May 17, 2020 0

Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell ... Read More

Seattle Genetics’ Adcetris receives FDA approval for peripheral T-cell lymphoma

pharmanewsdaily- November 18, 2018 0

Seattle Genetics' Adcetris, in combination with CHP chemotherapy, gains FDA approval for treating certain types of peripheral T-cell lymphoma. Seattle Genetics has announced that the ... Read More